Japan Tissue Engineering announced its interim financial results for the fiscal year ending March 2027, reporting ordinary income/loss of ¥7 million. The full-year forecast was unchanged from the previous forecast, with ordinary income/loss expected to be ¥110 million.
Japan Tissue Engineering announced its interim financial results for the fiscal year ending March 2027 on 30 October. Interim ordinary income/loss was ¥7 million.
In its full-year earnings forecast announced the same day, the company left its previous forecast unchanged and expects full-year ordinary income/loss of ¥110 million.
The company disclosed details of interim-period sales and its cost structure in its financial results summary, but this release highlights only the figures for the main items.
Market participants are closely watching the relationship between the interim results and the full-year forecast, while additional explanatory materials and future disclosures are awaited.